Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $26.25

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $26.25.

A number of equities analysts have recently commented on TARA shares. JPMorgan Chase & Co. lowered their price target on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. HC Wainwright reiterated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Oppenheimer upped their target price on Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th.

Protara Therapeutics Stock Performance

Protara Therapeutics stock opened at $4.09 on Friday. Protara Therapeutics has a 52 week low of $2.97 and a 52 week high of $7.82. The stock has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $5.24. The stock has a market capitalization of $229.86 million, a P/E ratio of -3.05 and a beta of 1.48.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. Research analysts forecast that Protara Therapeutics will post -1.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TARA. JPMorgan Chase & Co. bought a new stake in Protara Therapeutics in the 2nd quarter valued at about $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Protara Therapeutics in the second quarter worth $53,000. Persistent Asset Partners Ltd bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at about $57,000. AXQ Capital LP bought a new stake in Protara Therapeutics during the fourth quarter valued at approximately $58,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Protara Therapeutics during the 4th quarter worth $59,000. 38.13% of the stock is owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.